CalcMyPeptide
Weight ManagementAlso known as: LY3502970, ATTAIN trial, oral non-peptide GLP-1

Orforglipron

Orforglipron (by Eli Lilly) is a terrifyingly effective, absolute paradigm shift in metabolic medicine. Unlike Rybelsus (which is a fragile peptide forcefully dragged across the stomach lining using SNAC enhancers), Orforglipron is a true, synthetic non-peptide small molecule. Administered as a simple daily pill, it survives the stomach acid effortlessly and is currently annihilating Phase 3 trials, achieving near-injectable weight loss results (14.7%+) through pure oral delivery.

Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: Emerging1 peer-reviewed citation

Quick Stats

Half-Life~11 hours (oral, once daily)
Dose Range12-36-45 mg/day (oral)
Frequency1× daily (oral)
Vial SizesN/A (oral)
BioavailabilityHigh oral BA (no absorption enhancer needed)
Year Developed2022

Scientific Data

Molecular Formula
Small molecule (non-peptide)
Molecular Weight
~400–500 Da
Developer
Eli Lilly and Company

Mechanism of Action

Orforglipron (LY3502970) is a non-peptide, small-molecule oral GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide's oral form (Rybelsus, which requires a complex absorption enhancer and strict fasting), orforglipron is a small molecule taken orally without food restrictions. Phase 3 ATTAIN trials showed 9.4% body weight reduction over 40 weeks. Its oral convenience and no-fasting requirement could make it a preferred access point for GLP-1 therapy globally.

Source: PMID: 37351564 (Phase 2 NEJM)

Dosing Protocol

Typical Dose12-36-45 mg/day (oral)
Frequency1× daily (oral)
Half-Life~25-50 hours

Dosing Protocols

Phase 3 Doses

Dose
3 mg / 12 mg / 36 mg
Frequency
Once daily (oral)
Note: No food restrictions required — differentiator vs Rybelsus (semaglutide oral).

Administration

Route
Oral (capsule/tablet)
Timing
Once daily, any time, with or without food.
Fasting Required?
No — food timing not critical

Expected Timeline

Month 1-3
Appetite suppression and early weight loss.
Month 6-12
Phase 3: ~9.4% body weight reduction at highest dose over 40 weeks.

Who Is It For?

Obesity (Needle-Free)

High

Phase 3 data: 9.4% BWL. Key advantage — no injection required. Ideal for injection-averse patients.

Type 2 Diabetes

High

Phase 3 ATTAIN-T2DM: HbA1c reduction of 1.7% at 36 mg.

Safety & Considerations

Investigational — not FDA-approved as of early 2026. GI side effect profile consistent with GLP-1 class. NDA filing anticipated 2025-2026. No injection; no fasting window required.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Dosing Quick Reference

Orforglipron— Dosing Guide
Dose Range
12-36-45 mg/day (oral)
Half-Life
~25-50 hours
Frequency
1× daily (oral)
Route
Oral
Weight Managementcalcmypeptide.com

Frequently Asked Questions

How is orforglipron different from oral semaglutide (Rybelsus)?▼
Orforglipron is a true small molecule — no food or timing restrictions. Rybelsus (oral semaglutide) must be taken on empty stomach with ≤120mL water 30 min before eating. Orforglipron also doesn't require an absorption enhancer tablet.
Is orforglipron FDA-approved?▼
Not yet as of 2026. Phase 3 ATTAIN trials have reported results; FDA submission expected. Eli Lilly has stated submission is anticipated in 2025-2026.

References

  1. Dahl D et al. “"Orforglipron for obesity (Phase 3 ATTAIN)".” New England Journal of Medicine (2024).

📚 Related Articles

GLP-1 Dose Escalation Guide: Semaglutide, Tirzepatide & Retatrutide
14 min read • Pillar Guide

Looking for a trusted source? See our recommended suppliers →

Independently tested · COA-verified · Save 10% with our exclusive code

← Back to Peptide Library